Want to see PPBT full AI Analyst Report?
PPBT Stock Chart & Stats
$4.87
-$0.22(-5.25%)
At close: 4:00 PM EST
$4.87
-$0.22(-5.25%)
Day’s Range― - ―
52-Week Range$1.42 - $29.00
Previous CloseN/A
Volume16.93K
Average Volume (3M)415.61K
Market Cap
$10.88M
Enterprise Value-$3.60M
Total Cash (Recent Filing)$6.43M
Total Debt (Recent Filing)$184.00K
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Jul 30, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9933.94
Shares Outstanding1,621,046
10 Day Avg. Volume296,099
30 Day Avg. Volume415,608
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit67.58
Enterprise Value/Ebitda0.69
Forecast
1Y Price Target
$30.00Price Target Upside516.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Masked Tri‑specific T‑cell Engager PlatformThe CAPTN-3 masked tri-specific design materially improves the therapeutic window versus unmasked T‑cell engagers. Durable safety and PK advantages increase likelihood of clinical translatability, make the asset more attractive for partnerships, and differentiate Purple in crowded immuno‑oncology markets.
Focused R&D Strategy And Expert Scientific Advisory BoardManagement has centralized efforts on CAPTN-3, assembled an experienced SAB, and bolstered discovery with AI partnerships. This disciplined focus enhances trial design, prioritizes scarce resources toward highest-value programs, and raises the odds of efficient development and partner-readiness.
Low Financial LeverageA conservative capital structure with minimal debt reduces bankruptcy and interest‑payment risk, giving management flexibility to negotiate partnership deals or license structures. Low leverage is a persistent structural strength for a cash‑burning development biotech.
Bears Say
No Meaningful Revenue And Persistent LossesThe company lacks operating revenue and posts material, recurrent losses, which is a durable fundamental weakness. Continued negative earnings means ongoing financing need, dilutive capital raises, and no operating cushion until partnerships or product revenues materialize.
Limited Cash RunwayWith only modest cash on hand and runway into H1 2027, the company faces near-term funding requirements. This creates execution risk: trials or CMC investments could be delayed or require dilutive financing or partnership deals on constrained terms before clinical proof is achieved.
High Clinical And Execution Risk Concentrated In Preclinical LeadBusiness outcomes hinge on a preclinical lead moving into first‑in‑human studies and delivering proof‑of‑concept. This single‑asset concentration and multi‑year development timeline create binary risk: trial failure or delays would significantly impair partnership and commercialization prospects.
Purple Biotech News
PPBT FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $1.42 and its highest was $29.00 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is $10.88M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Jul 30, 2026 which is in 29 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on May 15, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.29.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -0.98.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,621,046 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went up 6.775%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
PPBT Stock 12 Month Forecast
Average Price Target
$30.00
▲(516.02% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.12% Other Institutional Investors
98.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---